TAB1 and ovarian cancer: Together, these results provide sufficient evidence to conclude that TFs of NF-κB1, c-Rel, and ELK1 transcriptionally repress miR-134 expression, thereby leading to TAB1 upregulation and contributing to ovarian cancer chemoresistance (Figure 6F).